Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014

Abstract

Hepatitis C virus (HCV) infection is considered by the World Health Organization (WHO) to be a serious public health concern and one of the major public health priorities. In 2005, it was estimated that there are 185 million anti-HCV positive people in the world, which constitutes 2.8% of the global population. Our study estimates the anti-HCV seroprevalence in the working age population (15–64 years-old), mostly urban and suburban residents, in Poland from 2004 to 2014. The studied group consisted of 61,805 working-age population representatives whose data were obtained from electronic medical records of an outpatient clinic network operating on a countrywide level. Positive anti-HCV test results were obtained in 957 patients, representing 1.5% of the whole population studied throughout the analysed period. The average age of all anti-HCV positive patients was 36.8 years. Analysis of the data suggests that the proportion of anti-HCV positive patients decreased over the study period (mean positive anti-HCV = -0.0017 × year + 3.3715; R2 = 0.7558). In 2004, positive results were noted among 3.2% of patients undergoing HCV antibody tests, but in 2014, the percentage of patients with a positive result stood at 1.1%. The apparent decrease affected men and women similarly. Our study also provides evidence that screening people born before 1965 could be beneficial.

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: A systematic review update

“…The other one reported 0.60% in the general female population. Subgroup analysis of age-specific prevalence was available for Italy [19,20] and Poland [21]. In Italy [19,20]…”

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020

“…The situation is not facilitated by the fact that so-called high-risk groups have lost their importance. Considering the low incidence of the infection in Poland, only widespread screening in the general population could provide identification of people unaware of the presence of the virus [ 1 - 4 ].…”

Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review

“…A recent WHO guideline recommended that HCV screening in birth cohorts of older persons at higher risk of infection and morbidity may be applied in populations with overall lower general prevalence, where indicated by the local epidemiology . Recent epidemiological studies to assess the relevance of such an approach have been performed in some EU/EEA countries, demonstrating the growing interest in this testing strategy and suggesting a possible role of this approach in the elimination effort . The evidence resulting from our study, however, indicated that the utility of birth cohort screening is dependent on the local epidemiology and context of the screening.…”